CClinicalTrials.gg
Sign In
CompletedNCT01602510Updated Jan 23, 2017Results posted

Lamotrigine Phase III Study in Bipolar I Disorder

A Phase 3 interventional study of Lamotrigine and Placebo in Bipolar Disorder, sponsored by GlaxoSmithKline. Completed at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-23.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This registration study in China is a multi-centre, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of lamotrigine in the prevention of recurrence/relapse of mood episodes in subjects with bipolar I disorder. Subjects are bipolar I disorder patients with recent/current manic, hypomanic, mixed or depressive episode. The study will include an open-label phase and a randomized phase. During the open-label phase, subjects will have lamotrigine monotherapy or combination therapy escalation. The target dose of lamotrigine is 200 milligram (mg)/day monotherapy. The duration of treatment in the open-label phase will last 6-16 weeks, until subjects reach a stable dose of lamotrigine. Beginning at week 7 of the open-label phase, subjects who have reached a stable dose of lamotrigine and met response criteria, defined as maintaining a Clinical Global Impression of Severity (CGI-S) score \<= 3 for at least 4 continuous weeks and maintaining lamotrigine 200 mg/day monotherapy for at least 1 week, will be eligible to enroll in the double-blind phase of the study. Subjects who have not met response criteria after 16 weeks of participation in the open-label phase will be withdrawn from the study. Subjects will have lamotrigine 200 mg/day monotherapy for at least 1 week prior to randomization. Subjects who have met randomization requirements will be randomized 1:1 to lamotrigine 200 mg/day or placebo for 36 weeks double-blind treatment. After randomization, subjects will be assessed at weekly intervals for the first month, biweekly intervals for the second month, and then at monthly intervals for up to 36 weeks of double-blind treatment. The primary endpoint will be TIME, defined as the time to intervention (addition of pharmacotherapy or electroconvulsive therapy [ECT]) for any mood episode (relapse or recurrence of a depressive, manic, hypomanic or mixed episode) after randomization. The secondary endpoints will include time to intervention for manic, hypomanic or mixed episode (TIMan) and time to intervention for depressive episode (TIDep).The scores on the Hamilton Depression (HAMD), Young Mania Rating Scale (YMRS), CGI-I, CGI-S and Global Assessment Scale (GAS) will be used as indicators for both intensity and duration of mood symptoms during this phase. Subjects who withdraw early from the study prior to week 36 or reach TIME will have a follow-up visit 14 days after the last dose of investigational drug.

02

Conditions studied

  • Bipolar Disorder

Browse trials for

03

In context

Bipolar Disorder

1,601 studies on the registry are indexed under Bipolar Disorder; 254 are open to participants now.

This study's enrollment of 265 is above the median of 64 across 1,223 interventional studies indexed under Bipolar Disorder.

Browse Bipolar Disorder studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.

Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

For open label phase

  • Subjects must be able to effectively communicate with study personnel, have the ability to comprehend the key components of the Inform Consent Form and must provide written informed consent to participate in the study prior to any study-specific assessments or procedures.
  • An in-patient or out-patient (male or female) and aged >=18 years old.

  • Disease to be studied: Has a diagnosis of the following disease as defined by DSM-IV criteria currently or within 60 days:

    a)Bipolar I Disorder, most recent episode depressed (296.5x); b)Bipolar I Disorder, most recent episode hypomanic (296.40); c)Bipolar I Disorder, most recent episode manic (296.4x); d)Bipolar I Disorder, most recent episode mixed (296.6x)

  • The subject who has a diagnose of "bipolar I disorder, most recent episode depressed (296.5x)" must meet the following criteria:

Has at least one well documented manic, hypomanic or mixed episode, as defined by DSM-IV criteria, within 3 years of enrolment ; The duration of recent/current depressive episode is at least 2 weeks but not longer than 12 months prior to enrolment; For subject with currently experiencing a depressive episode, he/she must have a minimum total score of 18 on the HAMD-17 at s screening.

  • The subject who has a diagnosis of "bipolar I disorder, most recent episode hypomanic (296.40)" or "bipolar I disorder, most recent episode manic (296.4x)" or "bipolar I disorder, most recent episode mixed (296.6x)" must meet the following criteria: Has had at least one well documented additional manic, hypomanic or mixed episode and one depressed episode, as defined by DSM-IV criteria, within 3 years of enrolment; Has a duration of the index manic episode of at least 1 week (unless hospitalised) or hypomanic episode of at least 4 days or mixed episode of at least 1 week. In neither case should the index episode be more than 12 months in duration; If the subject's index episode is the subject's initial/current manic mood event, subject must have a minimum score of 10 on the first 11 items of the YMRS at screening; If the subject's index episode is the subject's initial/current mixed mood event, subject must have a minimum score of 10 on the first 11 items of the YMRS, and have a minimum score of 18 on the HAMD-17 at screening.

For randomized double-blind phase

  • Has been on Lamotrigine 200 mg/day monotherapy for at least 1 week.
  • CGI-S score \<= 3 for at least 4 continuous weeks of treatment prior to randomization.
  • Has demonstrated adequate compliance with IP (compliance rate: 75%-125%, inclusive).

Exclusion criteria

Exclusion Criteria:

For open label

  • Has met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for rapid cycling and has had more than 4 manic, hypomanic, mixed or depressive episodes in the 12-month period prior to enrollment.
  • Has a significant DSM-IV Axis II diagnosis which would suggest non-responsiveness to pharmacotherapy for bipolar disorder or non-compliance with the protocol.
  • Has a current or previous diagnosis of an Axis I disorder (including anorexia nervosa or bulimia nervosa) with the exception of bipolar disorder or has received corresponding treatment, or has been diagnosed with dysthymia within the previous 2 years.
  • Has signs or symptoms of psychosis.
  • The subject, in the investigator's judgment, poses a suicidal risk, has attempted suicide within 6 months prior to screening (assessed using the Columbia Suicide Severity Rating Scale Baseline) or .
  • Has documented Intelligence quotient \< 70 or suspected mental retardation.
  • Has a history of substance abuse or dependence within 12 months prior to enrolment (DSM-IV defined substance categories, excluding nicotine and caffeine and including alcohol), or has as a positive urine test for illicit drug use (excluding nicotine and caffeine).
  • Has received fluoxetine within 4 weeks prior to entry into the open-label phase; has received oral contraceptives or other hormonal preparations containing estrogen within 2 weeks prior to entry into the open-label phase; has received lopinavir/ritonavir or atazanavir /ritonavir within 7 days prior to the baseline visit.
  • Has a clinically significant and/or unstable medical disorder (with or without lab test results); or clinically significant test results (thyroid function, electrocardiogram, hematology, clinical chemistry, or urinalysis) as per investigator's judgment; or a disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of lamotrigine; per investigator's clinical judgment (after consulting GSK medical monitor), might pose a safety concern; or interfere with the accurate assessment of safety or efficacy.
  • Has a history or current diagnosis of epilepsy.
  • Is morbidly obese, i.e. if Body Mass Index (BMI) is > 35 {BMI = Body weight (in kg) divided by (Height in meters squared).
  • Single or average QT interval corrected by Bazette's formulaQTcB or QTc > 450 millisecond (msec); for patients with bundle branch block QTc > 480 msec.
  • Has a history of hepatic dysfunction; Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) >= 2 x upper limit of normal (ULN); Alkaline phosphatase (ALP) or total bilirubin > 1.5 x ULN (excluding total bilirubin > 1.5 x ULN but direct bilirubin \< 35%) or other conditions which, in the investigator's judgment, would render patients unsuitable for the study.
  • Has a history of drug allergy (including rash) or a medically significant adverse effect from any ingredient of lamotrigine, or a history of rash due to anti-epileptic drugs or has frequent and/or serious hypersensitivity reaction to multiple drugs.
  • Participation in any study related to lamotrigine within 6 months before screening or has received lamotrigine within 4 weeks before screening.
  • Participation in another clinical study unrelated to the current illness currently or within the previous 30 days, or 3 months for studies related to the current illness.
  • Initiation of systematic psychotherapy within 3 months prior to screening or planned initiation of systematic psychotherapy during the study.
  • Female subjects who are pregnant, lactating or do not agree to use the contraceptive methods such as use of condom, injection of progesterone, a reliable barrier method of birth control, partner with vasectomy or abstinence during the study.

For randomized double blind phase

  • Has signs or symptoms of psychosis.
  • Requires treatment for a manic or mixed episode in the open-label phase with new courses of lithium, psychotropic drugs or other drugs with a half-life greater than 14 days.
  • Has become actively suicidal and/or has a score >=3 on item 3 of the HAMD.
  • Has tested positive for an illicit drug on lab analysis administered before randomization or alcohol abuse/addiction.
  • Has had a change in lamotrigine dosage during the last week of the open-label phase.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    Lamotrigine CD

    lamotrigine chewable dispersible tablets 25mg, 50mg, 100mg

    Drug: Lamotrigine

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugLamotrigine

    in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Time to Intervention for Any Mood Episode (TIME)

    TIME is defined as being the time from entry into the randomized double-blind phase to the time of the first prescription of any additional pharmacotherapy or Electroconvulsive therapy (ECT) determined by the investigator to be necessary for treatment of a relapse and/or recurrence of a depressive, manic, hypomanic or mixed episode, whichever occurs first. TIME was measured relative to randomization date. Par. prematurely discontinued from the study prior to reaching the TIME event were censored at the time of discontinuation. Analysis was performed using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction. The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level.

    Time frame: 36 weeks (wks)

Secondary outcomes

  1. Time to Intervention for Manic, Hypomanic or Mixed Episode (TIMan)

    TIMan was analyzed using using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction. The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level. Par. prematurely discontinued from the study prior to reaching the event were censored at the time of discontinuation.

    Time frame: 36 weeks

  2. Time to Intervention for Depressive Episode (TIDep)

    TIDep was analyzed using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction. The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level. Par. prematurely discontinued from the study prior to reaching the event were censored at the time of discontinuation.

    Time frame: 36 weeks

  3. Overall Survival in Study (TIME-SIS).

    TIME-SIS was defined as the time to intervention (addition of pharmacotherapy or ECT) for any mood episode, or to the time when the participant is withdrawn for any reason after randomization. The premature discontinuation of a participant prior to reaching TIME, for any reason, was treated as an event related to bipolar disorder. All participants prematurely discontinued prior to the TIME event in this analysis were to be assumed to have reached TIME. TIMS-SIS was analyzed using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction. The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level. Par. prematurely discontinued from the study prior to reaching the event were censored at the time of discontinuation.

    Time frame: 36 weeks

  4. Change From Baseline in Clinical Global Impression of Improvements (CGI-I)

    The CGI-I is a 7-point scale where investigator were asked to assess the participant's illness at the time of assessment (improved or worsened) relative to a baseline state. In this scale, 1= very much improved; 2= much improved; 3= minimally improved; 4= no change; 5= minimally worse; 6= much worse; or 7= very much worse. Analysis was performed using Analysis of covariance with covariates of site, CGI-S baseline score and treatment. In presented Last-observation-carried-forward datasets, the last non-missing on therapy (OT) score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period. Baseline value was defined as the last non-missing values at or prior to the randomization. Change from baseline at the time point of interest was calculated by subtracting the baseline values from the individual post-baseline values. If either baseline or post-baseline value was missing, the change from baseline was set to missing.

    Time frame: Baseline and up to 36 weeks

  5. Change From Baseline in Clinical Global Impression of Severity (CGI-S)

    The CGI-S is a 7-point scale where investigator were asked to rate the severity of the participant's illness at the time of assessment on severity of mental illness, where 1= normal, and 7= extremely ill. Data was collected on Weeks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32 and 36. Analysis performed using Analysis of Covariance (ANCOVA) with covariates of site, CGI-S baseline score (Open label phase), treatment and CGI-S baseline score. In presented Last observation carried forward (LOCF) datasets, last non-missing on therapy score prior to TIME was carried forward to estimate missing data points for remaining study visits of treatment period. The baseline value was defined as last non-missing values at or prior to the randomization. The change from baseline at the time point of interest was calculated by subtracting the baseline values from individual post-baseline values. If either the baseline or post-baseline value was missing, the change from baseline was set to missing as well.

    Time frame: Baseline and up to 36 weeks

  6. Change From Baseline in Hamilton Depression Rating Scale (HAMD)

    HAMD consists of 17 items: depressed mood, feelings of guilt, suicide, insomnia-early, middle, late, work and activities, retardation, agitation, anxiety psychic, anxiety somatic, somatic symptoms gastro-intestinal, general somatic symptoms, hypochondriasis, loss of weight, and insight. Investigators rated par. from 0 to 4 (or 2) for these items. Total score is sum of all subscales (0 to 52, higher is worse). Data was collected on Wks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 36. Analysis was performed using ANCOVA with covariates of site, CGI-S baseline (BL) score, treatment and HAMD total BL score. The last non-missing OT score prior to TIME was carried forward to estimate missing data points for remaining study visits of the treatment period. BL value was defined as the last non-missing value at or prior to the randomization. Change from BL was calculated by subtracting BL from the specific post-BL value. If BL or post-BL value was missing, the change from BL was set to missing.

    Time frame: Baseline and up to 36 weeks

  7. Change From Baseline in Young Mania Rating Scale (YMRS) Total Score

    YMRS consists of 11 items: Elevated Mood, Increased Motor Activity/Energy, Sexual Interest, Sleep, Irritability, Speech, Language/Thought Disorder, Content, Disruptive/Aggressive Behaviour, Appearance, and Insight. Investigators rated par. from 0 to 4 (or 8) for each of these items. Total score is the sum of all subscales, from 0 to 60 (higher is worse). Data was collected on Wks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 36. Analysis was performed using ANCOVA with covariates of site, CGI-S BL score, treatment and YMRS total BL score. In LOCF datasets, the last non-missing OT score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period. BL value was defined as the last non-missing values at or prior to the randomization. Change from BL at the time point of interest was calculated by subtracting BL value from the individual post-BL value. If either the BL or post-BL value was missing, change from BL was set to missing.

    Time frame: Baseline and up to 36 weeks

  8. Change From Baseline of Global Assessment Scale (GAS) Total Score

    For GAS, investigators rated par. for lowest level of functioning during the previous week. The scale has a 10 score categories: 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100, using intermediary levels when appropriate (from 100 to 1, Lower is worse.). Data was collected on Weeks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 36. Analysis was performed using ANCOVA with covariates of site, CGI-S BL score, treatment and GAS total BL score. In presented LOCF datasets, the last non-missing on therapy score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period. The BL value was defined as the last non-missing values at or prior to the randomization. The change from BL at the time point of interest was calculated by subtracting the BL values from the individual post-BL values. If either the BL or post-BL value was missing, the change from BL was set to missing as well.

    Time frame: Baseline and up to 36 weeks

  9. Change From Baseline in Body Weight

    Participant's body weight was measured on Weeks 0, 4, 8, 12, 16, 20, 24, 32 and 36. Analysis was performed using ANCOVA with covariates of site, CGI-S baseline score, treatment and baseline body weight. In presented LOCF datasets, the last non-missing on therapy score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period. The baseline value was defined as the last non-missing values at or prior to the randomization. The change from baseline at the time point of interest was calculated by subtracting the baseline values from the individual post-baseline values. If either the baseline or post-baseline value was missing, the change from baseline was set to missing as well.

    Time frame: Baseline and up to 36 weeks.

07

Results

Posted Jan 23, 2017

Participant flow

The study consisted of 4 phases: screen phase (\<2 weeks\[W\]), open-label phase (OLP) (Up to 16 W, lamotrigine monotherapy (LM) or combination therapy escalated to a target dose of LM 200 milligrams \[mg\]/day\[D\]), randomized double-blind phase (RDP) (up to 36 W, lamotrigine 200 mg/day or placebo) and follow-up visit (14 days after the last dose).

Open Label Phase
Participant flow — Open Label Phase
MilestoneOpen Label Lamotrigine 200 mg/DayRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Started42000
Completed11700
Not completed30300
Withdrew: Adverse event4600
Withdrew: Lack of efficacy2200
Withdrew: Protocol violation1500
Withdrew: Met protocol-defined stopping criteria12200
Withdrew: Lost to follow-up2200
Withdrew: Physician decision1900
Withdrew: Withdrawal by subject5700
Randomized Phase
Participant flow — Randomized Phase
MilestoneOpen Label Lamotrigine 200 mg/DayRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Started0133131
Completed05958
Not completed07473
Withdrew: Adverse event026
Withdrew: Lack of efficacy044
Withdrew: Protocol violation033
Withdrew: Met protocol-defined stopping criteria05848
Withdrew: Lost to follow-up013
Withdrew: Physician decision002
Withdrew: Withdrawal by subject067

Outcome measures

PrimaryTime to Intervention for Any Mood Episode (TIME)

TIME is defined as being the time from entry into the randomized double-blind phase to the time of the first prescription of any additional pharmacotherapy or Electroconvulsive therapy (ECT) determined by the investigator to be necessary for treatment of a relapse and/or recurrence of a depressive, manic, hypomanic or mixed episode, whichever occurs first. TIME was measured relative to randomization date. Par. prematurely discontinued from the study prior to reaching the TIME event were censored at the time of discontinuation. Analysis was performed using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction. The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level.

Time frame:
36 weeks (wks)
Reported as:
Median · Days
Time to Intervention for Any Mood Episode (TIME)
DaysRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Time to Intervention for Any Mood Episode (TIME)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.438 · Adjusted hazard ratio: 0.86 · 95% CI 0.59 to 1.25p value with Treatment Group as covariate
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.212 · Adjusted hazard ratio: 0.86 · 95% CI 0.59 to 1.25p value with Site as covariate
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.724 · Adjusted hazard ratio: 0.86 · 95% CI 0.59 to 1.25p value with CGI-S Baseline Score as covariate
SecondaryTime to Intervention for Manic, Hypomanic or Mixed Episode (TIMan)

TIMan was analyzed using using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction. The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level. Par. prematurely discontinued from the study prior to reaching the event were censored at the time of discontinuation.

Time frame:
36 weeks
Reported as:
Median · Days
Time to Intervention for Manic, Hypomanic or Mixed Episode (TIMan)
DaysRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Time to Intervention for Manic, Hypomanic or Mixed Episode (TIMan)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.869 · Adjusted hazard ratio: 0.95 · 95% CI 0.55 to 1.66p value with Treatment Group as covariate
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.061 · Adjusted hazard ratio: 0.95 · 95% CI 0.55 to 1.66p value with Site as covariate
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.505 · Adjusted hazard ratio: 0.95 · 95% CI 0.55 to 1.66p value with CGI-S Baseline Score as covariate
SecondaryTime to Intervention for Depressive Episode (TIDep)

TIDep was analyzed using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction. The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level. Par. prematurely discontinued from the study prior to reaching the event were censored at the time of discontinuation.

Time frame:
36 weeks
Reported as:
Median · Days
Time to Intervention for Depressive Episode (TIDep)
DaysRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Time to Intervention for Depressive Episode (TIDep)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.369 · Adjusted hazard ratio: 0.79 · 95% CI 0.48 to 1.32p value with Treatment Group as covariate
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.955 · Adjusted hazard ratio: 0.79 · 95% CI 0.48 to 1.32p value with Site as covariate
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.874 · Adjusted hazard ratio: 0.79 · 95% CI 0.48 to 1.32p value with CGI-S Baseline Score as covariate
SecondaryOverall Survival in Study (TIME-SIS).

TIME-SIS was defined as the time to intervention (addition of pharmacotherapy or ECT) for any mood episode, or to the time when the participant is withdrawn for any reason after randomization. The premature discontinuation of a participant prior to reaching TIME, for any reason, was treated as an event related to bipolar disorder. All participants prematurely discontinued prior to the TIME event in this analysis were to be assumed to have reached TIME. TIMS-SIS was analyzed using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction. The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level. Par. prematurely discontinued from the study prior to reaching the event were censored at the time of discontinuation.

Time frame:
36 weeks
Reported as:
Median · Days
Overall Survival in Study (TIME-SIS).
DaysRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Overall Survival in Study (TIME-SIS).183 (140 to NA)188 (117 to NA)
Statistical analysis
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.927 · Adjusted hazard ratio: 1.02 · 95% CI 0.73 to 1.40p value with Treatment Group as covariate
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.036 · Adjusted hazard ratio: 1.02 · 95% CI 0.73 to 1.40p value with Site as covariate
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · Regression, Cox · p = =0.509 · Adjusted hazard ratio: 1.02 · 95% CI 0.73 to 1.40p value with CGI-S Baseline Score as covariate
SecondaryChange From Baseline in Clinical Global Impression of Improvements (CGI-I)

The CGI-I is a 7-point scale where investigator were asked to assess the participant's illness at the time of assessment (improved or worsened) relative to a baseline state. In this scale, 1= very much improved; 2= much improved; 3= minimally improved; 4= no change; 5= minimally worse; 6= much worse; or 7= very much worse. Analysis was performed using Analysis of covariance with covariates of site, CGI-S baseline score and treatment. In presented Last-observation-carried-forward datasets, the last non-missing on therapy (OT) score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period. Baseline value was defined as the last non-missing values at or prior to the randomization. Change from baseline at the time point of interest was calculated by subtracting the baseline values from the individual post-baseline values. If either baseline or post-baseline value was missing, the change from baseline was set to missing.

Time frame:
Baseline and up to 36 weeks
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Clinical Global Impression of Improvements (CGI-I)
Score on a scaleRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Change From Baseline in Clinical Global Impression of Improvements (CGI-I)2.6 ± 0.202.7 ± 0.21
Statistical analysis
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · ANCOVA · p = =0.833 · Mean difference (final values): 0.0 · 95% CI -0.4 to 0.5
SecondaryChange From Baseline in Clinical Global Impression of Severity (CGI-S)

The CGI-S is a 7-point scale where investigator were asked to rate the severity of the participant's illness at the time of assessment on severity of mental illness, where 1= normal, and 7= extremely ill. Data was collected on Weeks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32 and 36. Analysis performed using Analysis of Covariance (ANCOVA) with covariates of site, CGI-S baseline score (Open label phase), treatment and CGI-S baseline score. In presented Last observation carried forward (LOCF) datasets, last non-missing on therapy score prior to TIME was carried forward to estimate missing data points for remaining study visits of treatment period. The baseline value was defined as last non-missing values at or prior to the randomization. The change from baseline at the time point of interest was calculated by subtracting the baseline values from individual post-baseline values. If either the baseline or post-baseline value was missing, the change from baseline was set to missing as well.

Time frame:
Baseline and up to 36 weeks
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Clinical Global Impression of Severity (CGI-S)
Score on a scaleRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Change From Baseline in Clinical Global Impression of Severity (CGI-S)0.7 ± 0.150.5 ± 0.15
Statistical analysis
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · ANCOVA · p = =0.245 · Mean difference (final values): -0.2 · 95% CI -0.5 to 0.1
SecondaryChange From Baseline in Hamilton Depression Rating Scale (HAMD)

HAMD consists of 17 items: depressed mood, feelings of guilt, suicide, insomnia-early, middle, late, work and activities, retardation, agitation, anxiety psychic, anxiety somatic, somatic symptoms gastro-intestinal, general somatic symptoms, hypochondriasis, loss of weight, and insight. Investigators rated par. from 0 to 4 (or 2) for these items. Total score is sum of all subscales (0 to 52, higher is worse). Data was collected on Wks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 36. Analysis was performed using ANCOVA with covariates of site, CGI-S baseline (BL) score, treatment and HAMD total BL score. The last non-missing OT score prior to TIME was carried forward to estimate missing data points for remaining study visits of the treatment period. BL value was defined as the last non-missing value at or prior to the randomization. Change from BL was calculated by subtracting BL from the specific post-BL value. If BL or post-BL value was missing, the change from BL was set to missing.

Time frame:
Baseline and up to 36 weeks
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Hamilton Depression Rating Scale (HAMD)
Score on a scaleRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Change From Baseline in Hamilton Depression Rating Scale (HAMD)3.0 ± 0.831.8 ± 0.84
Statistical analysis
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · ANCOVA · p = =0.155 · Mean difference (final values): -1.2 · 95% CI -3.0 to 0.5
SecondaryChange From Baseline in Young Mania Rating Scale (YMRS) Total Score

YMRS consists of 11 items: Elevated Mood, Increased Motor Activity/Energy, Sexual Interest, Sleep, Irritability, Speech, Language/Thought Disorder, Content, Disruptive/Aggressive Behaviour, Appearance, and Insight. Investigators rated par. from 0 to 4 (or 8) for each of these items. Total score is the sum of all subscales, from 0 to 60 (higher is worse). Data was collected on Wks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 36. Analysis was performed using ANCOVA with covariates of site, CGI-S BL score, treatment and YMRS total BL score. In LOCF datasets, the last non-missing OT score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period. BL value was defined as the last non-missing values at or prior to the randomization. Change from BL at the time point of interest was calculated by subtracting BL value from the individual post-BL value. If either the BL or post-BL value was missing, change from BL was set to missing.

Time frame:
Baseline and up to 36 weeks
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score
Score on a scaleRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score2.4 ± 0.872.8 ± 0.88
Statistical analysis
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · ANCOVA · p = = 0.661 · Mean difference (final values): 0.4 · 95% CI -1.4 to 2.2
SecondaryChange From Baseline of Global Assessment Scale (GAS) Total Score

For GAS, investigators rated par. for lowest level of functioning during the previous week. The scale has a 10 score categories: 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100, using intermediary levels when appropriate (from 100 to 1, Lower is worse.). Data was collected on Weeks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 36. Analysis was performed using ANCOVA with covariates of site, CGI-S BL score, treatment and GAS total BL score. In presented LOCF datasets, the last non-missing on therapy score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period. The BL value was defined as the last non-missing values at or prior to the randomization. The change from BL at the time point of interest was calculated by subtracting the BL values from the individual post-BL values. If either the BL or post-BL value was missing, the change from BL was set to missing as well.

Time frame:
Baseline and up to 36 weeks
Reported as:
Least squares mean · Score on a scale
Change From Baseline of Global Assessment Scale (GAS) Total Score
Score on a scaleRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Change From Baseline of Global Assessment Scale (GAS) Total Score-4.7 ± 1.75-4.9 ± 1.77
Statistical analysis
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · ANCOVA · p = = 0.945 · Mean difference (final values): -0.1 · 95% CI -3.7 to 3.5
SecondaryChange From Baseline in Body Weight

Participant's body weight was measured on Weeks 0, 4, 8, 12, 16, 20, 24, 32 and 36. Analysis was performed using ANCOVA with covariates of site, CGI-S baseline score, treatment and baseline body weight. In presented LOCF datasets, the last non-missing on therapy score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period. The baseline value was defined as the last non-missing values at or prior to the randomization. The change from baseline at the time point of interest was calculated by subtracting the baseline values from the individual post-baseline values. If either the baseline or post-baseline value was missing, the change from baseline was set to missing as well.

Time frame:
Baseline and up to 36 weeks.
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight
KilogramsRandomized PlaceboRandomized Lamotrigine 200 mg/Day
Change From Baseline in Body Weight-0.72 ± 0.399-1.56 ± 0.407
Statistical analysis
  • Randomized Placebo vs Randomized Lamotrigine 200 mg/Day · ANCOVA · p = =0.047 · Mean difference (final values): -0.84 · 95% CI -1.66 to -0.01

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study treatment and until the follow up contact (up to Study Day 230).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Placebo—3/133 (2.3%)46/133 (34.6%)
Randomized Lamotrigine 200 mg/Day—2/131 (1.5%)40/131 (30.5%)
Most frequent serious events
Most frequent serious events
EventRandomized PlaceboRandomized Lamotrigine 200 mg/Day
ManiaPsychiatric disorders2/1330/131
Suicide attemptPsychiatric disorders0/1331/131
Brain stem infarctionNervous system disorders0/1331/131
ConcussionInjury, poisoning and procedural complications1/1330/131
ContusionInjury, poisoning and procedural complications1/1330/131
LacerationInjury, poisoning and procedural complications1/1330/131
Most frequent other events
Showing 10 of 86
Most frequent other events
EventRandomized PlaceboRandomized Lamotrigine 200 mg/Day
NasopharyngitisInfections and infestations4/1334/131
HeadacheNervous system disorders4/1334/131
Urinary tract infectionInfections and infestations4/1333/131
Upper respiratory tract infectionInfections and infestations4/1332/131
Poor quality sleepNervous system disorders4/1332/131
Weight decreasedInvestigations1/1333/131
NauseaGastrointestinal disorders1/1333/131
FatigueGeneral disorders3/1332/131
Blood creatine phosphokinase increasedInvestigations1/1332/131
DiarrhoeaGastrointestinal disorders2/1332/131

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Open Label Lamotrigine 200 mg/Day
Mean35.7 ± 11.72
Gender
Gender(Participants)Open Label Lamotrigine 200 mg/Day
Female220
Male200
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Open Label Lamotrigine 200 mg/Day
Not Hispanic or Latino420
08

Study locations

21 sites
  • GSK Investigational Site
    Guangzhou, Guangdong 510180, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510370, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510630, China
  • GSK Investigational Site
    Baoding, Hebei 071000, China
  • GSK Investigational Site
    Shijiazhuang, Hebei 050000, China
  • GSK Investigational Site
    Harbin, Heilongjiang 150070, China
  • GSK Investigational Site
    Changsha, Henan 410011, China
  • GSK Investigational Site
    Xinxiang, Henan, China
  • GSK Investigational Site
    Wuhan, Hubei 430022, China
  • GSK Investigational Site
    Changsha, Hunan, China
  • GSK Investigational Site
    Nanjing, Jiangsu 210029, China
  • GSK Investigational Site
    Xi'an, Shaanxi 710032, China
  • GSK Investigational Site
    Taiyuan, Shanxi, China
  • GSK Investigational Site
    Chengdu, Sichuan 610041, China
  • GSK Investigational Site
    Kunming, Yunnan 650032, China
  • GSK Investigational Site
    Hangzhou, Zhejiang 310003, China
  • GSK Investigational Site
    Hangzhou, Zhejiang 310009, China
  • GSK Investigational Site
    Beijing, 100083, China
  • GSK Investigational Site
    Beijing, 100088, China
  • GSK Investigational Site
    Beijing, 100096, China
  • GSK Investigational Site
    Shanghai, 200030, China
09

References and documents

Publications

  • Zhang L, Zhang H, Lv LX, Tan Q, Xu X, Hu J, Zi L, Cooper J, Phansalkar A, Wang G. A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lamotrigine in the maintenance treatment of Chinese adult patients with bipolar I disorder. Int J Bipolar Disord. 2022 Aug 1;10(1):20. doi: 10.1186/s40345-022-00266-4. PubMed 35909213 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01602510
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 21, 2012
Start date
Aug 2012
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Jan 23, 2017
Last update
Jan 23, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Bipolar Disorder→

Other studies from this sponsor

GlaxoSmithKline

Start the discussion